Search results for "Protein"

showing 10 items of 21431 documents

Dentin degradonomics – The potential role of salivary MMP-8 in dentin caries

2019

Background Dentin caries involves dissolution of minerals which eventually leads to degradation of organic matrix. This degradation which was thought to be by bacterial proteases is now considered to be orchestrated by endogenous collagenases such as Matrix Metalloproteinases (MMPs). This paper aims to estimate the salivary levels of MMP-8 in dental caries and also to asses the various risk factors that contribute to the formation of dental caries. Material and methods A random sample of 75 adults aged 18-35 were included and categorized based on the number of caries lesions (MCL). Standard clinical examinations were performed, and stimulated saliva was collected and analyzed for concentrat…

medicine.medical_specialtySalivaOral Medicine and Pathologybusiness.industryResearch030206 dentistryMatrix metalloproteinase:CIENCIAS MÉDICAS [UNESCO]Positive correlationGastroenterology03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInternal medicineUNESCO::CIENCIAS MÉDICASDentinmedicineOrganic matrixMultiple linear regression analysis030212 general & internal medicineDentin cariesbusinessGeneral DentistryJournal of Clinical and Experimental Dentistry
researchProduct

Molecular adaptations of voltage-gated sodium ion channel related proteins after fatiguing stretch-shortening cycle exercise

2008

Dystrophin associated protein alpha-syntrophin is known to interact with voltage-gated sodium ion channel (NaCh). Dystrophin is known to be sensitive to eccentric muscle actions. For this reason, the function of the NaChs might also be affected. Molecular adaptations of dystrophin, alpha-syntrophin and NaChs were investigated after fatiguing stretch-shortening cycle (SSC) exercise, which consisted of unilateral jumps on a sledge apparatus. Muscle biopsies were taken from the vastus lateralis muscle of eight healthy subjects immediately after (IA) and 2 days after (2D) the exercise to analyze mRNA levels and immunohistochemical staining patterns. SSC exercise resulted in decreased isometric …

medicine.medical_specialtySarcolemmabiologyMuscle fatigueVastus lateralis muscleChemistrySodium channelPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseDystrophin-associated proteinEndocrinologyInternal medicinebiology.proteinmedicineEccentricOrthopedics and Sports MedicineDystrophinScandinavian Journal of Medicine & Science in Sports
researchProduct

Gender differences in skeletal muscle fibre damage after eccentrically biased downhill running in rats

1999

Specific antibodies against structural proteins of muscle fibres (actin, desmin, dystrophin) and extracellular matrix (fibronectin) were used to study the effect of eccentrically biased downhill running exercise (13,5 degrees, 17 m min(-1), 130 min) on the magnitude and properties of myofibre injury in the quadriceps femoris muscle of male and female rats. Muscle beta-glucuronidase activity, a quantitative indicator of muscle damage, showed clearly smaller increase in female than in male rats during the 4-day period following exercise. A similar course of histopathological changes was observed in both sexes, although females showed slower and less marked changes than males. In males, discon…

medicine.medical_specialtySarcolemmabiologyPhysiologyAnatomyQuadriceps femoris muscleLesionEndocrinologyInternal medicinemedicinebiology.proteinDesminmedicine.symptomCytoskeletonDystrophinMyofibrilActinActa Physiologica Scandinavica
researchProduct

Elevated plasma levels of cardiac troponin-I predict left ventricular systolic dysfunction in patients with myotonic dystrophy type 1: A multicentre …

2017

Objective:\ud \ud High sensitivity plasma cardiac troponin-I (cTnI) is emerging as a strong predictor of cardiac events in a variety of settings. We have explored its utility in patients with myotonic dystrophy type 1 (DM1).\ud Methods:\ud \ud 117 patients with DM1 were recruited from routine outpatient clinics across three health boards. A single measurement of cTnI was made using the ARCHITECT STAT Troponin I assay. Demographic, ECG, echocardiographic and other clinical data were obtained from electronic medical records. Follow up was for a mean of 23 months.\ud Results:\ud \ud Fifty five females and 62 males (mean age 47.7 years) were included. Complete data were available for ECG in 107…

medicine.medical_specialtySciencePopulationmacromolecular substances030204 cardiovascular system & hematologyMyotonic dystrophy03 medical and health sciences0302 clinical medicineInternal medicineTroponin IJournal ArticleMedicineOutpatient cliniccardiovascular diseaseseducationeducation.field_of_studyMultidisciplinarymedicine.diagnostic_testbiologybusiness.industryQRmedicine.diseaseTroponinSurgeryCohortAmbulatoryCardiologybiology.proteincardiovascular systemMedicinebusinessElectrocardiography030217 neurology & neurosurgeryPLoS ONE
researchProduct

Relationship between Skin Temperature Variation and Muscle Damage Markers after a Marathon Performed in a Hot Environmental Condition

2021

This study aimed to assess the effect of a marathon running at a hot environmental temperature on the baseline skin temperature (Tsk) of the posterior day and to analyze the relationship between Tsk response and muscle damage markers variation. The Tsk, creatine kinase, and lactate dehydrogenase of 16 marathon runners were assessed four times before (15 days and 45 min) and after (24 h and 6 days) a marathon in a hot environment (thermal stress index = 28.3 ± 3.3 °C and humidity ~81%). The Tsk of thirteen different body regions of both right and left lower limbs were analyzed. Higher values after the marathon were observed than 45 min before in creatine kinase (174.3 ± 136.4 UI/L &lt

medicine.medical_specialtyScienceVasodilationthermal imageMuscle damageArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compoundrecovery0302 clinical medicineLactate dehydrogenaseInternal medicinemedicineEcology Evolution Behavior and SystematicsendurancebiologyGlycogenbusiness.industrycreatine kinaseEndothelial nitric oxideQPaleontologySkin temperature030229 sport sciencesEndocrinologychemistrySpace and Planetary Scienceinfrared thermographybiology.proteinBody regionCreatine kinasebusinesshuman activities030217 neurology & neurosurgeryLife
researchProduct

Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System

2009

Nitric oxide (NO) produced by endothelial NO synthase (eNOS) represents an anti-atherosclerotic principle. NO bioavailability is decreased in atherosclerosis due to increased NO inactivation by reactive oxygen species and reduced NO synthesis. Various types of vascular pathophysiology are associated with oxidative stress, with NADPH oxidases as the major source of reactive oxygen species. These inactivate NO. Also, oxidative stress is likely to be the main cause for oxidation of the essential NOS cofactor, tetrahydrobiopterin (BH(4)). A lack of BH(4) leads to eNOS uncoupling (i.e., uncoupling of oxygen reduction from NO synthesis in eNOS). Based on these pathomechanisms, the therapeutic pot…

medicine.medical_specialtySepiapterinNitric Oxide Synthase Type IIImedicine.drug_classGTP cyclohydrolase INitric Oxidemedicine.disease_causeRenin inhibitorNitric oxidechemistry.chemical_compoundEnosInternal medicineDrug DiscoverymedicineAnimalsHumansHypolipidemic AgentsPharmacologybiologyArteriesTetrahydrobiopterinAtherosclerosisbiology.organism_classificationNitric oxide synthaseOxidative StressTreatment OutcomeEndocrinologychemistrybiology.proteinOxidative stressSignal Transductionmedicine.drugCurrent Pharmaceutical Design
researchProduct

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

2017

Abstract According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. The therapeutic approach for patients with homozygous familial hypercholesterolemia i…

medicine.medical_specialtySerine Proteinase InhibitorsDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciencesTherapeutic approach0302 clinical medicineRisk FactorsInternal medicineGermanyInternal MedicinemedicineHumans030212 general & internal medicinePCSK9 Inhibitorsbiologybusiness.industryPCSK9Anticholesteremic AgentsPCSK9 InhibitorsGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCombined Modality TherapyEndocrinologyTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component Removallipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoproteinLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct

One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?

2021

The recent ESC/EAS 2019 Guidelines for the management of dyslipidaemias are centred on the causal role of low density lipoprotein (LDL), or more generally apolipoprotein B (apoB)-containing lipoproteins, in atherosclerosis as an essential principle. Despite updated goals and recommendations, that have further highlighted the importance of a powerful reduction in LDL-C levels to reduce the individual CV risk, some challenges remain to be addressed in view of future guideline elaboration. In this review, we will summarize the new evidence from clinical trials since 2019 guideline release and discuss the possible challenges for the future.

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BControl (management)Guidelinechemistry.chemical_compoundRisk FactorsCardiovascular DiseasePrimary preventionCardiovascular disease DyslipidemiaInternal MedicineHumansMedicineIntensive care medicineDyslipidemiasSecondary preventionPrimary preventionbiologybusiness.industryCholesterolSecondary preventionLDL-C treatmentCholesterol LDLGuidelineAtherosclerosisClinical trialCholesterolchemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Risk Factors: AtherosclerosiHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessEuropean Journal of Internal Medicine
researchProduct

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct